ASCO 2009
Tomorrow, Iressa study will be revealed to the world.
Gene targetting drug, IRessa:
https://www.timesoftheinternet.com/78495.html
The new paradigm for cancer is personalized medicine, finding the right patient for the right drug.
To identify a gene group is a good step, but it still incompleted as you need a sceening tool to identify them.
KRAS mutation can now be effectivly and easily diagnost.
This basically validates further testing of 4601.
You know 4601 works on KRAS mut, you now have multiple tools to prescreen patients.
That's what a pharma is looking for.
Pharma have shifted research to identifying which person would benefit.
Once they find it, it's a GO decision for an oncology candidate.
A ready, open the box, drug = 4601.
4601 has everyhting for it.
-A huge market (RAS 30% of cancer).
-An identified sub group (KRAS patientt)
-Testing tools and biomarker available for KRAS
-Efficacy results in PI
-Orphan drug status for GBM
-Virtually no competitor... in the area..
Iressa revival marks a new day for cancer research...